Converge Coverage

HM20 Virtual product theaters: Aug. 25-27

Aug. 25, 2020. 12:00 p.m. – 1:00 p.m. ET

Medical Product Theater: Worsening Symptoms and Hospitalization for Heart Failure: Increased Risk of Poor Outcomes and Opportunities to Enhance Care

Objectives

  • Discuss hospitalization as a pivotal point in the clinical trajectory of heart failure.
  • Highlight strategies for improvement and optimization of the treatment plan for patients with heart failure.
  • Provide practical guidance for identifying predictors of worsening heart failure and educating on the importance of patients’ self-management.

Speaker

Dr. William T. Abraham

William T. Abraham, MD, FACP, FACC, FAHA, FESC, FRCPE

Professor of Medicine, Physiology, and Cell Biology

College of Medicine Distinguished Professor

Division of Cardiovascular Medicine

The Ohio State University,

Columbus, Ohio

Sponsored by Novartis Pharmaceuticals, and the faculty will be compensated for time.

Aug. 26, 2020. 12:00 p.m. – 1:00 p.m. ET

Commercial Product Theater: A First Choice Treatment for the Inpatient Management of Stabilized Systolic HF Patients: An Evidence-Based Approach

Description

Patients hospitalized due to heart failure with reduced ejection fraction (HFrEF) are at considerable risk of readmission and mortality. This program will review the benefits and risks of starting therapy in the hospital to help prevent rehospitalization and reduce patient mortality.

Speaker

Hameed Ali, DO, SFHM

Clinical Assistant Professor of Medicine

Baylor Scott and White Health

Dallas, Texas

Sponsored by Novartis Pharmaceuticals, and the faculty will be compensated for time.

Aug. 27, 2020. 12:00 p.m. – 1:00 p.m. ET

Commercial Product Theater: Selecting A First-Choice Therapy for Systolic HF: Meeting the Burden of Proof

Description

Dr. Javed Butler of Mississippi Medical Center, Jackson

Dr. Javed Butler

What is the burden of proof that needs to be met before a therapy can be selected for the treatment of systolic heart failure? Hear from Dr. Javed Butler, chairman of the Department of Medicine at the University of Mississippi Medical Center, to learn more about selecting a first-choice therapy for your patients with systolic heart failure.

In this program, Dr. Butler will discuss how aligning your therapy selection to pathophysiologic pathways for HFrEF, it is possible to reduce mortality and morbidity while providing a proven safety and tolerability profile.

Regardless of your patients’ previous heart failure treatment history, following this program, you can feel confident selecting your first-choice therapy for your patients with HFrEF.

Speaker

Javed Butler, MD, MPH, MBA

Chairman, Department of Medicine

University of Mississippi Medical Center,

Jackson, Mississippi

Sponsored by Novartis Pharmaceuticals, and the faculty will be compensated for time.

© Frontline Medical Communications 2018-2021. Reprinted with permission, all rights reserved.

Comment on this Article

Your email address will not be published. Required fields are marked *